TG02

Phase 1Small molecule

EEuropean Organisation for Research and Treatment of Cancer - EORTC

TG02 is one of 31 small molecule programs targeting Anaplastic Astrocytoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Anaplastic AstrocytomaActive, not recruiting

Anaplastic AstrocytomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

36 competitors in Anaplastic Astrocytoma

#DrugCompanyPhaseTrials

Gilenya

Actos

Istodax

Cialis

Ixempra

Paraplatin

Valtrex

GGlaxo Dba Glaxosmithkline

Approved

—8

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

—9

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

7 10

Ceenu

AAzurity Pharmaceuticals

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Anaplastic Astrocytoma1 trial

Multi-kinase Inhibitor TG02 (TG02) in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma.

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 1·NCT03224104·71 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TG02. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TG02 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TG02. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — European Organisation for Research and Treatment of Cancer - EORTC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: EEuropean Organisation for Research and Treatment of Cancer - EORTC

TG02

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Anaplastic Astrocytoma1 trial

References

Drug Info

Quick Facts

Related News